Horizon Provides $50M Venture Loan to Pelthos for Dermatology Expansion
Event summary
- Horizon Technology Finance provided a $50M venture loan facility to Pelthos Therapeutics, with $30M initially funded and $20M available for future growth.
- Pelthos commercializes ZELSUVMI™, an FDA-approved treatment for molluscum contagiosum, and recently acquired Xepi® Cream and Xeglyze®.
- Loan proceeds will support working capital and expansion of Pelthos' dermatology portfolio.
- Horizon, an affiliate of Monroe Capital, specializes in lending to life science and technology companies.
The big picture
Horizon’s $50M venture loan to Pelthos underscores the growing demand for specialized financing in the biopharmaceutical sector, particularly for companies targeting dermatology. The deal highlights the strategic importance of ZELSUVMI and Pelthos’ recent acquisitions in expanding treatment options for common skin infections. Horizon’s focus on life science companies aligns with broader industry trends toward targeted, non-dilutive funding solutions.
What we're watching
- Market Penetration
- How Pelthos will leverage the loan to expand ZELSUVMI’s market reach and integrate newly acquired products.
- Execution Risk
- Whether Pelthos can sustain growth while managing multiple product lines and regulatory compliance.
- Industry Trends
- The pace at which dermatology treatments adopt innovative delivery platforms like Nitricil.